Urinary DNA methylation biomarkers for prediction of prostate cancer upgrading and upstaging

• Published in: Clinical epigenetics Vol. 11; no. 1; p. 115
• Main Authors: Bakavicius, Arnas, Daniunaite, Kristina, Zukauskaite, Kristina, Barisiene, Marija, Jarmalaite, Sonata, Jankevicius, Feliksas
• Format: Journal Article
• Language: English
• Published: Germany BioMed Central Ltd 05.08.2019; BioMed Central
• Subjects: Biological markers; Biomarkers, Tumor - genetics; Biomarkers, Tumor - urine; Biopsy; Cancer genetics; Cancer patients; Cancer research; Cancer staging; Care and treatment; DNA; DNA Methylation; DNA, Neoplasm - urine; Epigenetic inheritance; Genes; Genetic research; Glutathione S-Transferase pi - genetics; Humans; Male; Medical tests; Methylation; Neoplasm Grading; Neoplasm Staging; Prostate cancer; Prostate-Specific Antigen - blood; Prostatectomy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Receptors, Retinoic Acid - genetics; Surgery; Tumor Suppressor Proteins - genetics; Tumors; Taiwan; Urine; DNA methylation; Upstaging; Upgrading; Prostate cancer
• ISSN: 1868-7075; 1868-7083; 1868-7083
• DOI: 10.1186/s13148-019-0716-z

Significant numbers of prostate cancer (PCa) patients experience tumour upstaging and upgrading in surgical specimens that cause serious problems in timely and proper selection of the treatment strategy. This study was aimed at the evaluation of a set of established epigenetic biomarkers as a noninvasive tool for more accurate PCa categorization before radical prostatectomy (RP). Quantitative methylation-specific PCR was applied for the methylation analysis of RARB, RASSF1, and GSTP1 in 514 preoperatively collected voided or catheterized urine samples from the single-centre cohort of 1056 treatment-naïve PCa patients who underwent RP. The rates of biopsy upgrading and upstaging were analysed in the whole cohort. Pathological examination of RP specimens revealed Gleason score upgrading in 27.2% and upstaging in 20.3% of the patients with a total misclassification rate of 39.0%. DNA methylation changes in at least one gene were detected in more than 80% of urine samples. Combination of the PSA test with the three-gene methylation analysis in urine was a significant predictor of pathological upstaging and upgrading (P < 0.050), however, with limited increase in overall accuracy. The PSA test or each gene alone was not informative enough. The urinary DNA methylation assay in combination with serum PSA may predict tumour stage or grade migration post-RP aiding in improved individual risk assessment and appropriate treatment selection. Clinical utility of these biomarkers should be proven in larger multi-centre studies.